BioNTech (BNTX) Expected to Announce Quarterly Earnings on Monday

BioNTech (NASDAQ:BNTX) will likely be posting its Q4 2025 results before the market opens on Monday, March 9th. Analysts expect the company to announce earnings of ($0.57) per share and revenue of $941.9940 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Tuesday, March 10, 2026 at 8:00 AM ET.

BioNTech Stock Performance

NASDAQ BNTX opened at $110.23 on Monday. The stock has a market capitalization of $24.82 billion, a price-to-earnings ratio of -41.91 and a beta of 1.51. The business’s 50 day moving average is $105.95 and its two-hundred day moving average is $103.41. BioNTech has a 12-month low of $81.20 and a 12-month high of $124.00. The company has a current ratio of 7.12, a quick ratio of 7.02 and a debt-to-equity ratio of 0.01.

Hedge Funds Weigh In On BioNTech

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. EFG International AG acquired a new stake in shares of BioNTech in the fourth quarter valued at approximately $29,000. Caitong International Asset Management Co. Ltd raised its position in shares of BioNTech by 520.0% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 310 shares of the company’s stock worth $30,000 after purchasing an additional 260 shares during the last quarter. Tower Research Capital LLC TRC lifted its stake in BioNTech by 118.2% in the 2nd quarter. Tower Research Capital LLC TRC now owns 563 shares of the company’s stock valued at $60,000 after buying an additional 305 shares in the last quarter. NewEdge Advisors LLC acquired a new stake in BioNTech during the 1st quarter valued at $167,000. Finally, Osaic Holdings Inc. grew its holdings in BioNTech by 27.3% during the 2nd quarter. Osaic Holdings Inc. now owns 1,949 shares of the company’s stock valued at $208,000 after buying an additional 418 shares during the last quarter. Institutional investors and hedge funds own 15.52% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on BNTX. UBS Group upgraded BioNTech to a “hold” rating in a research report on Thursday, December 4th. Berenberg Bank reaffirmed a “buy” rating on shares of BioNTech in a research note on Friday, January 23rd. Morgan Stanley reiterated an “overweight” rating and issued a $134.00 price objective on shares of BioNTech in a research note on Monday, November 3rd. The Goldman Sachs Group raised shares of BioNTech from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $115.00 to $142.00 in a report on Friday, January 16th. Finally, Leerink Partners cut shares of BioNTech from an “outperform” rating to a “market perform” rating and set a $113.00 target price for the company. in a report on Monday, February 2nd. Eleven equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $140.10.

BioNTech Company Profile

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.